- Home
- OGN vs CNTA Comparison
OGN vs CNTA Comparison
Compare OGN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGN
- CNTA
- Stock Information
- Founded
- OGN 1923
- CNTA 2020
- Country
- OGN United States
- CNTA United Kingdom
- Employees
- OGN N/A
- CNTA N/A
- Industry
- OGN Biotechnology: Pharmaceutical Preparations
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- OGN Health Care
- CNTA Health Care
- Exchange
- OGN Nasdaq
- CNTA Nasdaq
- Market Cap
- OGN 2.5B
- CNTA 2.3B
- IPO Year
- OGN N/A
- CNTA 2021
- Fundamental
- Price
- OGN $9.33
- CNTA $16.64
- Analyst Decision
- OGN Hold
- CNTA Strong Buy
- Analyst Count
- OGN 4
- CNTA 10
- Target Price
- OGN $18.00
- CNTA $30.56
- AVG Volume (30 Days)
- OGN 4.7M
- CNTA 1.0M
- Earning Date
- OGN 08-05-2025
- CNTA 08-12-2025
- Dividend Yield
- OGN 0.85%
- CNTA N/A
- EPS Growth
- OGN N/A
- CNTA N/A
- EPS
- OGN 2.69
- CNTA N/A
- Revenue
- OGN $6,281,000,000.00
- CNTA $15,000,000.00
- Revenue This Year
- OGN N/A
- CNTA N/A
- Revenue Next Year
- OGN $1.36
- CNTA N/A
- P/E Ratio
- OGN $3.50
- CNTA N/A
- Revenue Growth
- OGN N/A
- CNTA 118.88
- 52 Week Low
- OGN $8.01
- CNTA $9.60
- 52 Week High
- OGN $22.67
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- OGN 43.86
- CNTA 49.69
- Support Level
- OGN $8.95
- CNTA $16.27
- Resistance Level
- OGN $9.25
- CNTA $16.84
- Average True Range (ATR)
- OGN 0.28
- CNTA 0.70
- MACD
- OGN 0.00
- CNTA -0.21
- Stochastic Oscillator
- OGN 22.54
- CNTA 16.93
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.